The jawline has become one of the most requested treatment areas in aesthetic medicine. Allergan Aesthetics — now operating as part of AbbVie — responded with JUVÉDERM VOLUX XC: a product engineered specifically for the structural demands of the lower face. It represents a significant evolution in what is achievable with non-surgical facial contouring.
A Product Built for the Lower Face
The JUVÉDERM range uses VYCROSS technology — a proprietary cross-linking method that blends low and high molecular weight hyaluronic acid strands to produce gels of precisely controlled cohesivity, lift capacity, and longevity. VOLUX XC is the highest-lifting product in the range, with a G-prime (tissue resistance) specifically calibrated for placement in the deep fat compartments and periosteal plane of the jaw and chin.
Prior to VOLUX, practitioners were adapting existing products — VOLUMA, Teosyal RHA 4, Belotero Volume — for jawline work. Each required compromise: a product optimised for cheek projection might lack the precision needed for sharp mandibular definition. VOLUX XC was designed from the ground up for this anatomy, with a cohesive gel that holds its shape under the mechanical stress the lower face is subject to through talking, eating and facial expression.
Clinical Approval and Evidence
VOLUX XC received labelling approval in 2022 following a substantial clinical programme. Pivotal trials demonstrated statistically significant improvement in chin and jaw definition at 12 months, with high patient and clinician satisfaction scores. A majority of patients in Phase III studies reported satisfaction with their result at one year — a meaningful durability benchmark for a treatment in this area.
The product is placed using either a cannula or needle technique depending on the specific area. Chin body augmentation typically uses a small number of bolus injections placed supraperiosteally, while mandibular contouring along the ramus and angle uses a retrograde linear threading technique with a cannula, allowing smooth, natural-looking results without lumpiness.
Who Benefits Most
The ideal candidate for VOLUX treatment is someone experiencing age-related resorption of the mandibular bone and fat compartments, resulting in jowling or loss of lower face definition. It is equally effective for patients who have never had a well-defined jaw — whether through genetics or weight changes — and are seeking structural improvement rather than correction of volume loss. Male patients in particular have driven significant growth in lower face treatment, with jawline definition representing a more gender-congruent goal than lip or cheek treatments.
As with all structural filler work, patient selection and thorough assessment are paramount. In patients where significant skin laxity is the primary concern, soft tissue lifting through threads or radiofrequency may be more appropriate — or a combined approach may serve best. Tracy assesses each patient's full facial anatomy before recommending any injectable plan.
The Importance of Product Knowledge
Not all HA fillers behave the same way in tissue, and using the wrong product for the wrong indication introduces unnecessary risk. An experienced injector understands not just the technique but the rheological properties of each product in their hands — how it flows, where it migrates, how long it lasts, and what happens if dissolution with hyaluronidase is required. VOLUX XC, used correctly by a trained practitioner, produces results that were simply not achievable non-surgically a decade ago.